Ozempic显示全球增长强劲,减少了心脏风险和糖尿病肾衰减,并正在开发新的口服替代品。 Ozempic shows strong global growth, reducing heart risks and kidney decline in diabetics, with new oral alternatives in development.

OZEMPIC（司美格鲁肽）在全球2型糖尿病、肥胖和心血管风险降低方面持续强劲增长，实际数据显示，与度拉肽相比，重大不良心血管事件风险降低了23%。 OZEMPIC (semaglutide) continues to see strong global growth for type 2 diabetes, obesity, and cardiovascular risk reduction, with real-world data showing a 23% lower risk of major adverse cardiovascular events compared to dulaglutide. 这是唯一获准减少患慢性肾脏疾病的糖尿病患者不断恶化的肾病的GLP-1 RA。 It is the only GLP-1 RA approved to reduce worsening kidney disease in diabetic patients with chronic kidney disease. 诺沃·诺迪斯克(Novo Nordisk)在2025年启动了每月499美元的接入计划,以提高可负担性,而正在进行的试验则探索了阿尔茨海默氏病、肝硬化和1型糖尿病的用途。 Novo Nordisk launched a $499 monthly access program in 2025 to improve affordability, while ongoing trials explore uses in Alzheimer’s, liver cirrhosis, and type 1 diabetes. 在第三阶段试验中口服GLP-1 RA的Orforglipron(口服GLP-1 RA)表明,在最近的研究中,与口服硫酸相比,体重减幅较高,HbA1c(口服硫酸盐)的情况有所改善,预计今后几年可能会得到批准。 Orforglipron, an oral GLP-1 RA in Phase III trials, showed superior weight loss and HbA1c improvements over oral semaglutide in recent studies, with potential approval expected in the coming years.